SCHEMBL24614079

SCHEMBL24614079

O=CC[C@H]1CC[C@H](NC(=O)c2cc3ccccc3[nH]2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 6/20 0.54
▸ DRD3 P35462 6/20 0.54
▸ SMYD3 Q9H7B4 4/20 0.53
▸ KDM4E B2RXH2 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ GAA P10253 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ CYP2D6 P10635 2/20 0.51
▸ HTR1D P28221 2/20 0.51
▸ HTR1B P28222 2/20 0.51
▸ HTR1A P08908 1/20 0.51
▸ HTR2A P28223 1/20 0.51
▸ MAOB P27338 1/20 0.50
▸ SLC2A1 P11166 1/20 0.50
▸ SCN4A P35499 1/20 0.49
▸ SCN9A Q15858 1/20 0.49
▸ MLLT1 Q03111 1/20 0.49
▸ CHRNA7 P36544 1/20 0.48
▸ HTR3A P46098 1/20 0.48
▸ FAAH O00519 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4018254 0.87 KDM4E (0.62) DRD2DRD3SMYD3KDM4EALDH1A1
SCHEMBL24614077 0.84 AKR1C3 (0.62) DRD2DRD3SMYD3KDM4EALDH1A1
SCHEMBL24076389 0.83 SLC6A2 (0.64) DRD2DRD3SMYD3KDM4EALDH1A1
SCHEMBL30301379 0.83 SLC6A2 (0.64) DRD2DRD3SMYD3KDM4EALDH1A1
SCHEMBL75198 0.82 MLLT1 (0.65) DRD2DRD3SMYD3KDM4EALDH1A1
SCHEMBL76132 0.82 MLLT1 (0.69) SMYD3KDM4EALDH1A1GAAMAPK1
SCHEMBL19837662 0.81 NPC1 (0.56) DRD2DRD3SMYD3KDM4EALDH1A1
SCHEMBL21490113 0.81 SMYD3 (0.71) SMYD3KDM4EALDH1A1GAAMAPK1
SCHEMBL19710676 0.81 SMYD3 (0.71) SMYD3KDM4EALDH1A1GAAMAPK1
SCHEMBL19850663 0.81 NPC1 (0.56) DRD2DRD3SMYD3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220220102-A1 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2022-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220102-A1 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF DRD3, ADRB3, VDR DRD2 7/4885DRD3 1/4885SMYD3 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback